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Heparin cofactor II (HC II) and thrombin were chemically modified with pyridoxal S-phosphate, and their 
effects on the inhibition of thrombin by HC II in the presence of heparin or dermatan sulfate were studied. 
The inhibition of thrombin by HC II was enhanced about 7000-fold in the presence of heparin or dermatan 
sulfate. However, this enhancement by heparin dwindled to 1 lo- and 9.6-fold when the modified HC II and 
the modified thrombin, respectively, were substituted for native proteins. Essentially identical results were 
obtained from the experiments using dermatan sulfate. These results indicate that the binding of heparin 
or dermatan sulfate to both thrombin and HC II is required for the sulfated polysaccharide-dependent accel- 
eration of the thrombin inhibition by HC II, and the binding to thrombin is more essential for the reaction. 
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1. INTRODUCTION 
Heparin cofactor II (HC II) is a plasma protease 
inhibitor which inhibits thrombin by forming a 
stable 1 : 1 molar complex [l-5]. It is well known 
that the thrombin inhibitory activity of HC II is 
dramatically accelerated by some sulfated polysac- 
charides such as heparin, dermatan sulfate [6], 
dextran sulfate [7], chondroitin polysulfates [8] 
and pentosan polysulfate [9]. However, the 
mechanism of the action of these sulfated polysac- 
charides to accelerate the interaction between HC 
II and thrombin is still controversial. Griffith [IO] 
presented the kinetic evidence that heparin is 
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bound to both HC II and thrombin, forming a ter- 
nary complex. On the other hand, more recently, 
it has been suggested from the chemical modifica- 
tion of HC II that the binding of heparin to HC II 
is essential for the reaction [11,12]. Here, we pre- 
sent new evidence to support the model of a ter- 
nary complex formation [lo] and show that the 
binding of heparin or dermatan sulfate to throm- 
bin is more essential than that to HC II for the 
heparin- or dermatan sulfate-accelerated thrombin 
inhibition by HC II. 
2. EXPERIMENTAL 
Porcine mucosa heparin (168 units/mg, A4, 
7000-20000) and porcine skin dermatan sulfate 
(Mr 2000040000) were purchased from Sigma and 
Seikagaku Kogyo, respectively. Both polysac- 
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charides are free from other polysaccharides [8]. 
HC II and thrombin were purified from human 
plasma as described in [7,13], and chemically 
modified with pyridoxa15 ‘-phosphate as described 
in [11,14], respectively. Modified proteins were ap- 
plied to a heparin-Sepharose CLdB column 
equilibrated with 0.1 M triethanolamine (pH 
7.8)/O. 1 M NaCI/O. 1% polyethyleneglycol at 
room temperature, and the pass-through fractions 
were pooled and used in subsequent experiments. 
HC II and thrombin treated similarly but in the 
absence of pyridoxa15 ’ -phosphate were used as in- 
tact proteins. The incorporation of pyridoxal 
5 ‘-phosphate into protein was determined from 
absorbance at 322 nm using an extinction coeffi- 
cient of 9000 M-’ *cm-’ [14]. The second-order 
rate constant (k”) of the HC II-thrombin interac- 
tion was determined using a synthetic substrate 
[151. 
In this paper, the inhibition of intact thrombin 
by intact HC II and that by modified HC II are 
referred to as inhibitions A and B, respectively, 
and the inhibition of modified thrombin by intact 
HC II and that by modified HC II as inhibitions C 
and D, respectively. 
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Fig.1. Kinetics of thrombin inhibition by HC II in the 
presence of heparin. Second-order rate constants (k”) of 
inhibitions A (intact thrombin and intact HC II) (o), B 
(intact thrombin and modified HC II) (A), C (modified 
thrombin and intact HC II) (D) and D (modified 
thrombin and modified HC II) (0) were plotted as a 
function of heparin concentration. Rate constants were 
determined according to [15]. 
3. RESULTS 
To abolish the heparin-binding abilities of HC II 
and thrombin, these two proteins were 
phosphopyridoxylated according to [ 11,141. When 
the modified proteins were applied to a heparin- 
Sepharose column as described in section 2, about 
95 or 60% of HC II or thrombin, respectively, was 
passed through the column. The pass-through 
fractions were pooled and used in subsequent ex- 
periments so that proteins retaining the heparin- 
binding ability were completely avoided. 
HC II and thrombin incorporated 4.1 and 
2.7 mol per mol, respectively, of pyridoxal 
5 ‘-phosphate, which resulted in the loss of their 
heparin-binding abilities without significant loss of 
their inhibitory and amidolytic activities, respec- 
tively. These results are consistent with [l 1,141. 
Heparin-independent k” of the inhibition of 
modified thrombin by intact HC II (inhibition C) 
and that by modified HC II (inhibition D) were 
almost identical to that of the inhibition of intact 
thrombin by intact HC II (inhibition A), giving a 
value of about 5 x lo4 M-’ . min-‘. This value of 
heparin-independent k” of inhibition A is about 
lo-fold lower than that reported by Tollefsen et al. 
[3] but is equal to that reported by Griffith et al. 
[5,11]. However, heparin-independent k” of the 
104h 
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Fig.2. Kinetics of thrombin inhibition by HC II in the 
presence of dermatan sulfate. Experiments were 
conducted as described in fig.1 except that dermatan 
sulfate was used instead of heparin. 
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inhibition of intact thrombin by modified HC II of the modification of thrombin was much more 
(inhibition B) increased to 3.3 x lo5 M-’ omin-’ striking than that of HC II, indicating that the 
for unknown reasons. This phenomenon has also binding of heparin to thrombin is more essential 
been described in [ 111. for the acceleration by heparin. 
Effects of phosphopyridoxylations of HC II 
and/or thrombin on the heparin-dependent inhibi- 
tion of thrombin by HC II are shown in fig.1. A 
modification of either protein resulted in a 
remarkable decrease of the maximum k” of the 
reaction between HC II and thrombin. The 
decrease in k” of inhibition C was much more 
striking than that of inhibition B, giving the max- 
imum k” of 3.2 x lo*, 3.6 x 107, 4.7 x lo5 and 
5.7 x lo4 M-l. min-’ for inhibitions A, B, C and 
D, respectively. 
Essentially identical results were obtained from 
the experiments using dermatan sulfate. In both 
cases, the loss of heparin-binding or dermatan 
sulfate-binding ability of thrombin resulted in a 
more drastic decrease of the sulfated 
polysaccharide-dependent acceleration of the 
thrombin inhibition by HC II. These results also 
indicate that lysine residues of both HC II and 
thrombin are essential for their dermatan sulfate- 
binding abilities. 
Unexpectedly, no decrease in k” of inhibition B 
and C was observed even in the presence of excess 
amounts of heparin, while k” of inhibition A 
decreased at heparin concentrations above 
50 pg/ml. It should also be pointed out that k’ ’ of 
inhibition B was saturated at a heparin concentra- 
tion of 100 pg/ml, while inhibition C was 
saturated at as low as 1 lug/ml heparin. 
Essentially identical results were obtained from 
experiments using dermatan sulfate as sulfated 
polysaccharide (fig.2), although the difference of 
k” between inhibition B and C was slightly smaller 
than that in the case of heparin, giving a maximum 
k” of 3.8 x lo*, 1.6 x 107, 5.4 x lo5 and 9.6 x 
lo4 M-’ amin-’ for inhibitions A, B, C and D, 
respectively. 
Results analogous to ours have been reported 
for the inhibition of thrombin by antithrombin III 
in the presence of heparin. Pomerantz and Owen 
[16] and Griffith [14] demonstrated that heparin 
could not enhance the thrombin inhibition by an- 
tithrombin III when the heparin-binding ability of 
thrombin was abolished by a modification of 
arginyl or lysyl residues. Based on these and subse- 
quent studies [ 171, a ternary complex (or a 
template) model in which heparin is simultaneous- 
ly bound to both thrombin and antithrombin III 
has generally been accepted. 
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